Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/196208
Title: | Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study |
Author: | Saura, Ouriel Rouzé, Anahita Martin Loeches, Ignacio Povoa, Pedro Kreitmann, Louis Torres Martí, Antoni Metzelard, Matthieu Du Cheyron, Damien Lambiotte, Fabien Tamion, Fabienne Labruyere, Marie Boulle Geronimi, Claire Luyt, Charles-Edouard Nyunga, Martine Pouly, Olivier Thille, Arnaud Wilfrid Megarbane, Bruno Saade, Anastasia Magira, Eleni Llitjos, Jean-François Ioannidou, Iliana Pierre, Alexandre Reignier, Jean Garot, Denis Baudel, Jean-Luc Voiriot, Guillaume Plantefeve, Gaëtan Morawiec, Elise Asfar, Pierre Boyer, Alexandre Mekontso-Dessap, Armand Bardaka, Fotini Diaz, Emili Vinsonneau, Christophe Floch, Pierre-Edouard Weiss, Nicolas Ceccato, Adrian Artigas, Antonio Nora, David Duhamel, Alain Labreuche, Julien Nseir, Saad coVAPid Study Group |
Keywords: | COVID-19 Pneumònia Corticosteroides Infeccions respiratòries Respiració artificial Respiradors COVID-19 Pneumonia Adrenocortical hormones Respiratory infections Artificial respiration Respirators |
Issue Date: | 27-Sep-2023 |
Publisher: | BioMed Central |
Abstract: | Background: Ventilator-associated pneumonia (VAP) is common in patients with severe SARS-CoV-2 pneumonia. The aim of this ancillary analysis of the coVAPid multicenter observational retrospective study is to assess the relationship between adjuvant corticosteroid use and the incidence of VAP. Methods: Planned ancillary analysis of a multicenter retrospective European cohort in 36 ICUs. Adult patients receiving invasive mechanical ventilation for more than 48 h for SARS-CoV-2 pneumonia were consecutively included between February and May 2020. VAP diagnosis required strict definition with clinical, radiological and quantitative microbiological confirmation. We assessed the association of VAP with corticosteroid treatment using univariate and multivariate cause-specific Cox's proportional hazard models with adjustment on pre-specified confounders. Results: Among the 545 included patients, 191 (35%) received corticosteroids. The proportional hazard assumption for the effect of corticosteroids on the incidence of VAP could not be accepted, indicating that this effect varied during ICU stay. We found a non-significant lower risk of VAP for corticosteroid-treated patients during the first days in the ICU and an increased risk for longer ICU stay. By modeling the effect of corticosteroids with time-dependent coefficients, the association between corticosteroids and the incidence of VAP was not significant (overall effect p = 0.082), with time-dependent hazard ratios (95% confidence interval) of 0.47 (0.17-1.31) at day 2, 0.95 (0.63-1.42) at day 7, 1.48 (1.01-2.16) at day 14 and 1.94 (1.09-3.46) at day 21. Conclusions: No significant association was found between adjuvant corticosteroid treatment and the incidence of VAP, although a time-varying effect of corticosteroids was identified along the 28-day follow-up. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s13054-022-04170-2 |
It is part of: | Critical Care, 2023, vol. 26, num. 1, p. 292 |
URI: | http://hdl.handle.net/2445/196208 |
Related resource: | https://doi.org/10.1186/s13054-022-04170-2 |
ISSN: | 1364-8535 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
730082.pdf | 1.11 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License